The latest price target for Hims & Hers Health (NYSE:HIMS) was reported by Canaccord Genuity on December 2, 2024. The analyst firm set a price target for $38.00 expecting HIMS to rise to within 12 months (a possible 17.14% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Hims & Hers Health (NYSE:HIMS) was provided by Canaccord Genuity, and Hims & Hers Health maintained their buy rating.

The last upgrade for Hims & Hers Health Inc happened on February 9, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Hims & Hers Health Inc.

The last downgrade for Hims & Hers Health Inc happened on November 14, 2024 when B of A Securities changed their price target from $32 to $18 for Hims & Hers Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hims & Hers Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hims & Hers Health was filed on December 2, 2024 so you should expect the next rating to be made available sometime around December 2, 2025.

While ratings are subjective and will change, the latest Hims & Hers Health (HIMS) rating was a maintained with a price target of $28.00 to $38.00. The current price Hims & Hers Health (HIMS) is trading at is $32.44, which is within the analyst’s predicted range.